. Author manuscript; available in PMC: 2016 May 1.

Published in final edited form as: Arterioscler Thromb Vasc Biol. 2015 Mar 26;35(5):1071–1079. doi: 10.1161/ATVBAHA.115.305085

Table 2. Pre-clinical data on the effects of imatinib on EC barrier dysfunction.

Several independent groups have demonstrated that imatinib enhances endothelial barrier function and protects against vascular leak in vitro and in vivo. However, some data demonstrate increased leak after imatinib in other injury models.

In vitro models	Agonist	Effect on EC barrier
Rat aortic EC	VEGF	Protective⁸²
HUVEC	Thrombin, Histamine	Protective¹⁰
HLMVEC	Thrombin	Protective¹⁰
Immortalized EC	VEGF	Protective¹¹
HUVEC	SCF	Protective⁷⁹
Mouse lung microvascular EC	H₂O₂	Protective¹³
HPAEC	LPS	Protective¹²
HPAEC	18% CS	Disruptive¹²
Murine models
Bleomycin-induced ALI	Bleomycin	*Anti-inflammatory⁸³
CLP (sepsis)	Fecal peritonitis	Protective¹⁰
Isolated perfused lung	TRAP	Protective¹⁰
Isolated perfused lung	Ischemia/ reperfusion	*Attenuates cytotoxicity¹³
IT LPS (neutropenic mice)	LPS	Protective⁹
IT LPS	LPS	Protective¹²
Miles assay	VEGF	Protective¹⁰
Miles assay	VEGF	Protective⁷⁹
Miles assay	VEGF	Protective¹¹
VILI	MV (30 mL/kg tidal volume)	Disruptive¹²

CLP – cecal ligation and puncture, LPS - lipopolysaccharide, TRAP - thrombin receptor activating peptide, VEGF - vascular endothelial growth factor, VILI - ventilator-induced lung injury, MV – mechanical ventilation.